Samsara Vision, announced it will collaborate with Lansheng Medical “MyVision”, a China-based company focused on ophthalmology, to develop a comprehensive clinical and commercial organization to support Samsara Vision's SING IMT™ (Smaller-Incision New-Generation Implantable Miniature Telescope) in mainland China, Macau, the Hanain Province, and Hong Kong. MyVision will execute the clinical program necessary for regulatory approval, commercialize the SING IMT™, coordinate reimbursement, and drive sales, marketing, and customer relationships. MyVision will be responsible for securing market approvals for the SING IMT™ in mainland China, Macau, and the Hainan Province.

In Hong Kong, the device already has a CE mark. MyVision will also contribute to Samsara Vision's global strategic team, providing context on the patient and physician voice in Asia. Worldwide, AMD is the is the leading cause of blindness in people 55 and older in developed countries.

Studies estimate that there are more than 26 million people living in China with any form of AMD and, of those, nearly 6 million progressed to late-stage AMD, meaning a person has irreversible central vision loss in both eyes. Of those, Samsara Vision estimates that 1.3 million people may be candidates for the SING IMT™. Due to the aging population, it is estimated that the prevalence of AMD in China will increase to more than 55 million people by 2050.